Arcutis Biotherapeutics (ARQT) Net Cash Flow Growth (3y) (2022 - 2026)

Arcutis Biotherapeutics (ARQT) Net Cash Flow Growth (3y) (2022 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) NCF Growth (3y) (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -8.34%
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 36.60%
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 106.37%
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 114.55%
7 Royalty Pharma 33.72 Bn 35.84 Bn - 4.55%
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 67.39%
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 52.78%
10 Arcutis Biotherapeutics 3.29 Bn 3.05 Bn 118.92 Mn -26.52%

Historic Data

Download Data
DateValue
Jun 30, 2026 -26.52%
Mar 31, 2026 -31.84%
Dec 31, 2025 46.50%
Sep 30, 2025 -48.49%
Jun 30, 2025 62.73%
Mar 31, 2025 12.22%
Dec 31, 2024 -50.61%
Sep 30, 2024 49.65%
Jun 30, 2024 19.06%
Mar 31, 2024 -23.16%
Dec 31, 2023 -42.85%
Sep 30, 2023 26.40%
Jun 30, 2023 47.74%
Mar 31, 2023 -40.03%
Dec 31, 2022 -39.16%
Sep 30, 2022 24.61%
Jun 30, 2022 6.78%
Mar 31, 2022 -18.16%